Origene
Who owns Origene?
Origene is a Chinese Healthcare company, now owned by Vcanbio Cell & Gene Engineering, which acquired it in 2021 from Cathay Capital.
Hand-verified · updated 2026-04-21
Open JSON · CC-BY
Key facts
- ·Fully exited in 2021 to Vcanbio Cell & Gene Engineering.
- ·Average hold across 2 realized cycles: 4 years.
Ownership history
2 ownership periods · co-invest detected
Cathay Capital sold Origene to Vcanbio Cell & Gene Engineering in 2021 after 6 years.
Merieux Equity Partners sold Origene to Shanghai Aoyuan Investment Management Co. in 2016 after 1 year.
More from Cathay Capital Midcap I
Other portfolio companies in the same fund.
France
USMore PE-backed in Healthcare
Comparable healthcare deals from other GPs.
Questions
Who owns Origene?
Origene is now owned by Vcanbio Cell & Gene Engineering, which acquired it in 2021 from Cathay Capital.
When did Vcanbio Cell & Gene Engineering acquire Origene?
Vcanbio Cell & Gene Engineering acquired Origene in 2021, buying from Cathay Capital.
Who did Origene sell to?
Cathay Capital sold Origene to Vcanbio Cell & Gene Engineering in 2021 (Trade Sale). Merieux Equity Partners sold Origene to Shanghai Aoyuan Investment Management Co. in 2016 (Trade Sale).
Who has owned Origene over time?
Origene has been through 2 private-equity ownership periods: Cathay Capital · via Cathay Capital Midcap I · 2015–2021 · sold to Vcanbio Cell & Gene Engineering · (Trade Sale); Merieux Equity Partners · via Mérieux Innovation 1 · 2015–2016 · sold to Shanghai Aoyuan Investment Management Co. · (Trade Sale).